The Impact of Radiopharmaceutical Therapy on Renal Function
- 18 March 2022
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 52 (4) , 467-474
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Rise or fall of glomerular filtration rate: does it matter?Kidney International, 2013
- The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2013
- Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation studyJournal of Translational Medicine, 2013
- Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?European Journal of Nuclear Medicine and Molecular Imaging, 2011
- The Origin of Multiple Molecular Forms in Urine of HNL/NGALClinical Journal of the American Society of Nephrology, 2010
- Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for PreventionJournal of Nuclear Medicine, 2010
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (Ethyol®)European Journal of Cancer, 1996
- Mechanisms of tubulointerstitial fibrosisKidney International, 1991
- The linear-quadratic formula and progress in fractionated radiotherapyBritish Journal of Radiology, 1989